Researchers with City of Hope and Memorial Sloan Kettering (MSK) Cancer Center have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient’s likely response to chimeric antigen receptor (CAR) T cell therapy before starting the treatment, according to study results published in Nature Medicine.
Leave A Comment